Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis

JACC: Cardiovascular Imaging

Volumn 12, Issue 2, 2019, Pages 283-296

  Bing, Rong ^a   Cavalcante, João L ^b   Everett, Russell J ^a   Clavel, Marie Annick ^c   Newby, David E ^a   Dweck, Marc R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

aortic stenosis; cardiac magnetic resonance; late gadolinium enhancement; myocardial fibrosis; T1 mapping

Indexed keywords

GADOLINIUM;

AORTIC STENOSIS; AORTIC VALVE REPLACEMENT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; DIAGNOSTIC IMAGING; EXTRACELLULAR VOLUME FRACTION; HEART MUSCLE FIBROSIS; HUMAN; INDEXED EXTRACELLULAR VOLUME; PRIORITY JOURNAL; REVIEW; AORTIC VALVE; AORTIC VALVE STENOSIS; CARDIAC MUSCLE; FIBROSIS; HEART LEFT VENTRICLE FUNCTION; HEART VALVE REPLACEMENT; HEART VENTRICLE REMODELING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; X-RAY COMPUTED TOMOGRAPHY;

AORTIC VALVE; AORTIC VALVE STENOSIS; FIBROSIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85060537069     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2018.11.026     Document Type: Review

References (91)

1. Nkomo, V.T., Gardin, J.M., Skelton, T.N., Gottdiener, J.S., Scott, C.G., Enriquez-Sarano, M., Burden of valvular heart diseases: a population-based study. Lancet 368 (2006), 1005–1011.
2. Iung, B., Vahanian, A., Epidemiology of valvular heart disease in the adult. Nat Rev Cardiol 8 (2011), 162–172.
3. Osnabrugge, R.L., Mylotte, D., Head, S.J., et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol 62 (2013), 1002–1012.
4. Dweck, M.R., Boon, N.A., Newby, D.E., Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol 60 (2012), 1854–1863.
5. Rosenhek, R., Zilberszac, R., Schemper, M., et al. Natural history of very severe aortic stenosis. Circulation 121 (2010), 151–156.
6. Coffey, S., Cox, B., Williams, M.J., The prevalence, incidence, progression, and risks of aortic valve sclerosis: a systematic review and meta-analysis. J Am Coll Cardiol 63 (2014), 2852–2861.
7. Genereux, P., Stone, G.W., O'Gara, P.T., et al. Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptomatic severe aortic stenosis. J Am Coll Cardiol 67 (2016), 2263–2288.
8. Durko, A.P., Osnabrugge, R.L., Van Mieghem, N.M., et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J 39 (2018), 2635–2642.
9. Leon, M.B., Smith, C.R., Mack, M., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363 (2010), 1597–1607.
10. Smith, C.R., Leon, M.B., Mack, M.J., et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364 (2011), 2187–2198.
11. Adams, D.H., Popma, J.J., Reardon, M.J., et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370 (2014), 1790–1798.
12. Leon, M.B., Smith, C.R., Mack, M.J., et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374 (2016), 1609–1620.
13. Reardon, M.J., Van Mieghem, N.M., Popma, J.J., et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376 (2017), 1321–1331.
14. Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), e57–e185.
15. Baumgartner, H., Falk, V., Bax, J.J., et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 38 (2017), 2739–2791.
16. Krayenbuehl, H.P., Hess, O.M., Monrad, E.S., Schneider, J., Mall, G., Turina, M., Left-ventricular myocardial structure in aortic-valve disease before, intermediate, and late after aortic-valve replacement. Circulation 79 (1989), 744–755.
17. Hein, S., Arnon, E., Kostin, S., et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107 (2003), 984–991.
18. Yotti, R., Bermejo, J., Gutierrez-Ibanes, E., et al. Systemic vascular load in calcific degenerative aortic valve stenosis: insight from percutaneous valve replacement. J Am Coll Cardiol 65 (2015), 423–433.
19. Lindman, B.R., Otto, C.M., Douglas, P.S., et al. Blood pressure and arterial load after transcatheter aortic valve replacement for aortic stenosis. Circ Cardiovasc Imaging, 10, 2017, e006308.
20. Pawade, T.A., Newby, D.E., Dweck, M.R., Calcification in aortic stenosis: the skeleton key. J Am Coll Cardiol 66 (2015), 561–577.
21. Kandalam, V., Basu, R., Moore, L., et al. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress. Circulation 124 (2011), 2094–2105.
22. Weber, K.T., Brilla, C.G., Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991), 1849–1865.
23. Heymans, S., Schroen, B., Vermeersch, P., et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112 (2005), 1136–1144.
24. Yang, W., Wang, B.H., Wang, I., et al. Inhibition of apoptosis signal-regulating kinase 1 attenuates myocyte hypertrophy and fibroblast collagen synthesis. Heart Lung Circ, 12, 2017, e0187459.
25. Treibel, T.A., Kozor, R., Schofield, R., et al. Reverse myocardial remodeling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol 71 (2018), 860–871.
26. Treibel, T.A., Lopez, B., Gonzalez, A., et al. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J 39 (2018), 699–709.
27. Weidemann, F., Herrmann, S., Stork, S., et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 120 (2009), 577–584.
28. Azevedo, C.F., Nigri, M., Higuchi, M.L., et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 56 (2010), 278–287.
29. Herrmann, S., Stork, S., Niemann, M., et al. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol 58 (2011), 402–412.
30. Yilmaz, A., Kindermann, I., Kindermann, M., et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 122 (2010), 900–909.
31. Weng, Z., Yao, J., Chan, R.H., et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. J Am Coll Cardiol Img 9 (2016), 1392–1402.
32. Raina, S., Lensing, S.Y., Nairooz, R.S., et al. Prognostic value of late gadolinium enhancement cmr in systemic amyloidosis. J Am Coll Cardiol Img 9 (2016), 1267–1277.
33. Hulten, E., Agarwal, V., Cahill, M., et al. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging, 9, 2016, e005001.
34. Di Marco, A., Anguera, I., Schmitt, M., et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. J Am Coll Cardiol HF 5 (2017), 28–38.
35. Halliday, B.P., Gulati, A., Ali, A., et al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation 135 (2017), 2106–2115.
36. Aquaro, G.D., Perfetti, M., Camastra, G., et al. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study. J Am Coll Cardiol 70 (2017), 1977–1987.
37. Ganesan, A.N., Gunton, J., Nucifora, G., McGavigan, A.D., Selvanayagam, J.B., Impact of late gadolinium enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol 254 (2018), 230–237.
38. Becker, M.A.J., Cornel, J.H., van de Ven, P.M., van Rossum, A.C., Allaart, C.P., Germans, T., The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a review and meta-analysis. J Am Coll Cardiol Img 11 (2018), 1274–1284.
39. Shah, A.S., Chin, C.W., Vassiliou, V., et al. Left ventricular hypertrophy with strain and aortic stenosis. Circulation 130 (2014), 1607–1616.
40. Chin, C.W., Shah, A.S., McAllister, D.A., et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 35 (2014), 2312–2321.
41. Chin, C.W.L., Everett, R.J., Kwiecinski, J., et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. J Am Coll Cardiol Img 10 (2017), 1320–1333.
42. Everett, R.J., Tastet, L., Clavel, M.A., et al. Progression of hypertrophy and myocardial fibrosis in aortic stenosis: a multicenter cardiac magnetic resonance study. Circ Cardiovasc Imaging, 11, 2018, e007451.
43. Chen, H., Zeng, J., Liu, D., Yang, Q., Prognostic value of late gadolinium enhancement on CMR in patients with severe aortic valve disease: a systematic review and meta-analysis. Clin Radiol, 73, 2018, 983 e7–14.
44. Dweck, M.R., Joshi, S., Murigu, T., et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 58 (2011), 1271–1279.
45. Barone-Rochette, G., Pierard, S., De Meester de Ravenstein, C., et al. Prognostic significance of LGE by CMR in aortic stenosis patients undergoing valve replacement. J Am Coll Cardiol 64 (2014), 144–154.
46. Musa, T.A., Treibel, T.A., Vassiliou, V.S., et al. Myocardial scar and mortality in severe aortic stenosis. Circulation 138 (2018), 1935–1947.
47. Dweck, M., Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS (EVoLVeD). Available at: https://clinicaltrials.gov/ct2/show/NCT03094143. (Accessed 2 May 2018)
48. Puntmann, V.O., Peker, E., Chandrashekhar, Y., Nagel, E., T1 mapping in characterizing myocardial disease: a comprehensive review. Circ Res 119 (2016), 277–299.
49. Taylor, A.J., Salerno, M., Dharmakumar, R., Jerosch-Herold, M., T1 mapping: basic techniques and clinical applications. J Am Coll Cardiol Img 9 (2016), 67–81.
50. Look, D.C., Locker, D.R., Time saving in measurement of NMR and EPR relaxation times. Review of Scientific Instruments 41 (1970), 250–251.
51. Messroghli, D.R., Radjenovic, A., Kozerke, S., Higgins, D.M., Sivananthan, M.U., Ridgway, J.P., Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med 52 (2004), 141–146.
52. Piechnik, S.K., Ferreira, V.M., Dall'Armellina, E., et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson, 12, 2010, 69.
53. Puntmann, V.O., Carr-White, G., Jabbour, A., et al. T1-mapping and outcome in nonischemic cardiomyopathy: all-cause mortality and heart failure. J Am Coll Cardiol Img 9 (2016), 40–50.
54. Puntmann, V.O., Carr-White, G., Jabbour, A., et al. Native T1 and ECV of noninfarcted myocardium and outcome in patients with coronary artery disease. J Am Coll Cardiol 71 (2018), 766–778.
55. Bull, S., White, S.K., Piechnik, S.K., et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart 99 (2013), 932–937.
56. Lee, S.P., Lee, W., Lee, J.M., et al. Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis. Radiology 274 (2015), 359–369.
57. Kockova, R., Kacer, P., Pirk, J., et al. Native T1 relaxation time and extracellular volume fraction as accurate markers of diffuse myocardial fibrosis in heart valve disease- comparison with targeted left ventricular myocardial biopsy. Circ J 80 (2016), 1202–1209.
58. Lee, H., Park, J.B., Yoon, Y.E., et al. Noncontrast myocardial T1 mapping by cardiac magnetic resonance predicts outcome in patients with aortic stenosis. J Am Coll Cardiol Img 11 (2018), 974–983.
59. Chin, C.W., Semple, S., Malley, T., et al. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging 15 (2014), 556–565.
60. Podlesnikar, T., Delgado, V., Bax, J.J., Cardiovascular magnetic resonance imaging to assess myocardial fibrosis in valvular heart disease. Int J Cardiovasc Imaging 34 (2018), 97–112.
61. Dabir, D., Child, N., Kalra, A., et al. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson, 16, 2014, 69.
62. Flett, A.S., Hayward, M.P., Ashworth, M.T., et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 122 (2010), 138–144.
63. Ugander, M., Oki, A.J., Hsu, L.Y., et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 33 (2012), 1268–1278.
64. Wong, T.C., Piehler, K., Meier, C.G., et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 126 (2012), 1206–1216.
65. Miller, C.A., Naish, J.H., Bishop, P., et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging 6 (2013), 373–383.
66. White, S.K., Sado, D.M., Fontana, M., et al. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. J Am Coll Cardiol Img 6 (2013), 955–962.
67. Treibel, T.A., Fontana, M., Maestrini, V., et al. Automatic measurement of the myocardial interstitium: synthetic extracellular volume quantification without hematocrit sampling. J Am Coll Cardiol Img 9 (2016), 54–63.
68. Robison, S., Karur, G.R., Wald, R.M., Thavendiranathan, P., Crean, A.M., Hanneman, K., Noninvasive hematocrit assessment for cardiovascular magnetic resonance extracellular volume quantification using a point-of-care device and synthetic derivation. J Cardiovasc Magn Reson, 20, 2018, 19.
69. Messroghli, D.R., Moon, J.C., Ferreira, V.M., et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson, 19, 2017, 75.
70. Nagata, Y., Takeuchi, M., Wu, V.C., et al. Prognostic value of LV deformation parameters using 2D and 3D speckle-tracking echocardiography in asymptomatic patients with severe aortic stenosis and preserved LV ejection fraction. J Am Coll Cardiol Img 8 (2015), 235–245.
71. Hwang, J.W., Kim, S.M., Park, S.J., et al. Assessment of reverse remodeling predicted by myocardial deformation on tissue tracking in patients with severe aortic stenosis: a cardiovascular magnetic resonance imaging study. J Cardiovasc Magn Reson, 19, 2017, 80.
72. Chin, C.W., Messika-Zeitoun, D., Shah, A.S., et al. A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis. Eur Heart J 37 (2016), 713–723.
73. Spuentrup, E., Ruhl, K.M., Botnar, R.M., et al. Molecular magnetic resonance imaging of myocardial perfusion with EP-3600, a collagen-specific contrast agent: initial feasibility study in a swine model. Circulation 119 (2009), 1768–1775.
74. Wildgruber, M., Bielicki, I., Aichler, M., et al. Assessment of myocardial infarction and postinfarction scar remodeling with an elastin-specific magnetic resonance agent. Circ Cardiovasc Imaging 7 (2014), 321–329.
75. Song, F., Parekh, S., Hooper, L., et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess, 14, 2010 iii, ix–xi, 1–193.
76. Ross, J. Jr., Braunwald, E., Aortic stenosis. Circulation 38 (1968), 61–67.
77. Fontana, M., White, S.K., Banypersad, S.M., et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson, 14, 2012, 88.
78. Flett, A.S., Sado, D.M., Quarta, G., et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging 13 (2012), 819–826.
79. Debl, K., Djavidani, B., Buchner, S., et al. Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis. Heart 92 (2006), 1447–1451.
80. Rudolph, A., Abdel-Aty, H., Bohl, S., et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 53 (2009), 284–291.
81. Rajesh, G.N., Thottian, J.J., Subramaniam, G., Desabandhu, V., Sajeev, C.G., Krishnan, M.N., Prevalence and prognostic significance of left ventricular myocardial late gadolinium enhancement in severe aortic stenosis. Indian Heart Journal 69 (2017), 742–750.
82. de Meester de Ravenstein, C., Bouzin, C., Lazam, S., et al. Histological validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T. J Cardiovasc Magn Reson, 17, 2015, 48.
83. Child, N., Suna, G., Dabir, D., et al. Comparison of MOLLI, shMOLLLI, and SASHA in discrimination between health and disease and relationship with histologically derived collagen volume fraction. Eur Heart J Cardiovasc Imaging 19 (2018), 768–776.
84. Dusenbery, S.M., Jerosch-Herold, M., Rickers, C., et al. Myocardial extracellular remodeling is associated with ventricular diastolic dysfunction in children and young adults with congenital aortic stenosis. J Am Coll Cardiol 63 (2014), 1778–1785.
85. Bandula, S., White, S.K., Flett, A.S., et al. Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings. Radiology 269 (2013), 396–403.
86. Hong, Y.J., Kim, T.K., Hong, D., et al. Myocardial characterization using dual-energy CT in doxorubicin-induced DCM: comparison with CMR T1-mapping and histology in a rabbit model. J Am Coll Cardiol Img 9 (2016), 836–845.
87. Treibel, T.A., Fontana, M., Steeden, J.A., et al. Automatic quantification of the myocardial extracellular volume by cardiac computed tomography: synthetic ECV by CCT. J Cardiovasc Comput Tomogr 11 (2017), 221–226.
88. Nacif, M.S., Kawel, N., Lee, J.J., et al. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology 264 (2012), 876–883.
89. Nacif, M.S., Liu, Y., Yao, J., et al. 3D left ventricular extracellular volume fraction by low-radiation dose cardiac CT: assessment of interstitial myocardial fibrosis. J Cardiovasc Comput Tomogr 7 (2013), 51–57.
90. Treibel, T.A., Bandula, S., Fontana, M., et al. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J Cardiovasc Comput Tomogr 9 (2015), 585–592.
91. Lee, H.J., Im, D.J., Youn, J.C., et al. Myocardial extracellular volume fraction with dual-energy equilibrium contrast-enhanced cardiac CT in nonischemic cardiomyopathy: a prospective comparison with cardiac MR Imaging. Radiology 280 (2016), 49–57.